Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464504 | 1.00 | TUBB1 (0.58) | TUBB1ABCG2NPC1LMNAGAA | |
| SCHEMBL4462141 | 0.88 | ABCG2 (0.61) | ABCG2NPC1LMNAGAAMAPT | |
| SCHEMBL4462137 | 0.88 | ABCG2 (0.61) | ABCG2NPC1LMNAGAAMAPT | |
| SCHEMBL4467307 | 0.84 | ABCG2 (0.53) | ABCG2NPC1LMNAGAAMAPT | |
| SCHEMBL4467303 | 0.84 | ABCG2 (0.53) | ABCG2NPC1LMNAGAAMAPT | |
| SCHEMBL4461547 | 0.82 | PPARA (0.64) | TUBB1ABCG2ALDH1A1KRASATM | |
| SCHEMBL11893118 | 0.82 | PPARA (0.64) | TUBB1ABCG2ALDH1A1KRASATM | |
| SCHEMBL3970547 | 0.80 | F3 (0.69) | MAPTALDH1A1KRASMEN1KMT2A | |
| SCHEMBL3970548 | 0.80 | F3 (0.69) | MAPTALDH1A1KRASMEN1KMT2A | |
| SCHEMBL9806815 | 0.79 | LMNA (0.61) | TUBB1ABCG2NPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701938-B1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2012-07-25 | — | — | EP | claimed |
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | GENFIT (FR) | 2008-03-06 | — | — | US | claimed |
| JP-2007517841-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1701938-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | Genfit (FR) | 2006-09-20 | — | — | EP | claimed |
| WO-2005073184-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2005-08-11 | — | — | WO | claimed |
| EP-1701938-B1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-7547729-B2 | 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same | GENFIT (FR) | 2009-06-16 | — | — | US | disclosed |
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | GENFIT (FR) | 2008-03-06 | — | — | US | disclosed |
| EP-1701938-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | Genfit (FR) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005073184-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | TYR, DHPS, DDT | TUBB1 2665/4885ABCG2 2092/4885NPC1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.